MedTrace Logo

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

NCT02579564 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2016-10-21

No results posted yet for this study

Summary

The purpose of this multi-center clinical trial is to verify more effective on local control of malignant pleural effusions in NSCLC patients by thoracic cavity perfusion of recombinant human adenovirus type 5 injection and recombinant human Endostatin injection (Endostar) compared with cisplatin perfusion, with acceptable side effects.

Conditions

  • Malignant Hydrothorax
  • Non Small Cell Lung Cancer

Interventions

DRUG

Gemcitabine

DRUG

Vinorelbine

DRUG

Paclitaxel

DRUG

Pemetrexed

DRUG

Oncorine

DRUG

Endostar

DRUG

Cisplatin

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-06-30
Completion
2018-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02579564 on ClinicalTrials.gov